# Pain and Psychiatry: Chronic Pain Management and the Opioid Crisis

## Introduction

Chronic pain and psychiatric illness share a bidirectional relationship that is among the most challenging clinical problems in modern medicine. Depression, anxiety, PTSD, and substance use disorders are all significantly more prevalent in chronic pain populations. The ongoing **opioid crisis** has placed psychiatrists in a critical role, both in managing co-occurring pain and mental illness, and in addressing opioid use disorder.

## The Biopsychosocial Model of Pain

Pain is never purely nociceptive; it is always a **subjective, multidimensional experience**. **Biological factors**: tissue damage, central sensitization, neuroplastic changes, genetic vulnerability. **Psychological factors**: catastrophizing, fear-avoidance, depression, anxiety, trauma history. **Social factors**: disability status, litigation, social isolation, cultural expectations of pain expression. The **fear-avoidance model** explains how catastrophic interpretation of pain leads to avoidance, deconditioning, and disability.

## Neurobiological Overlap Between Pain and Depression

Chronic pain and depression share common neural circuits: **anterior cingulate cortex, insula, prefrontal cortex, periaqueductal gray**. Shared neurotransmitter systems: serotonin, norepinephrine, and endogenous opioid pathways. Central sensitization in chronic pain parallels neuroplastic changes seen in mood disorders. **Inflammatory cytokines** (IL-6, TNF-alpha) are elevated in both chronic pain and depression.

![Diagram showing overlapping neural circuits and neurotransmitter systems between chronic pain and depression](/images/psychiatry/pain-depression-neural-overlap.png)

## Psychiatric Comorbidity in Chronic Pain

Major depression: present in **30-50%** of chronic pain patients. Anxiety disorders: **20-40%** prevalence. PTSD: particularly elevated in chronic pain after injury or trauma. Substance use disorders: risk increases with duration of opioid therapy. Personality disorders: may complicate treatment alliance and pain management.

## The Opioid Crisis: Scope and Context

Over **100,000** drug overdose deaths annually in the United States (as of recent CDC data) The crisis evolved in three waves: prescription opioids (1990s), heroin (2010), synthetic opioids/fentanyl (2013-present) Factors contributing to the crisis: aggressive pharmaceutical marketing, inadequate pain education, prescriber habits, lack of access to addiction treatment. **Psychiatric patients** are disproportionately affected due to higher rates of pain, trauma, and substance use vulnerability.

## Opioid Prescribing Principles

Follow **CDC guidelines**: opioids are not first-line for chronic non-cancer pain. If opioids are used, start with the lowest effective dose for the shortest duration. Avoid concurrent benzodiazepine and opioid prescribing (increased overdose risk) Use **prescription drug monitoring programs (PDMPs)** before prescribing. Screen for opioid use disorder risk using the **Opioid Risk Tool (ORT)** or **SOAPP-R**. Prescribe **naloxone** for overdose reversal to all patients on chronic opioid therapy.

## Non-Opioid Pharmacotherapy for Chronic Pain

| Drug Class | Examples | Pain Indications | Dose for Pain | Dual Psychiatric Benefit |
|-----------|---------|-----------------|---------------|-------------------------|
| SNRIs | Duloxetine, venlafaxine | Neuropathic, fibromyalgia, musculoskeletal | Duloxetine 60-120 mg/day | Depression, anxiety |
| TCAs | Amitriptyline, nortriptyline | Neuropathic, headache, fibromyalgia | 10-75 mg HS (sub-antidepressant) | Depression, insomnia |
| Anticonvulsants | Gabapentin, pregabalin | Neuropathic pain | Gabapentin 300-3600 mg/day | Anxiety, insomnia |
| Anticonvulsants | Carbamazepine | Trigeminal neuralgia | 200-1200 mg/day | Mood stabilization |
| Topicals | Lidocaine patch, capsaicin | Localized neuropathic pain | Apply locally | None systemic |
| NMDA antagonists | Ketamine (IV/IN) | Treatment-resistant pain | Variable | Depression |
| SSRIs | Fluoxetine, sertraline | Limited pain evidence | Standard doses | Depression, anxiety |

### Antidepressants

**SNRIs** (duloxetine, venlafaxine): first-line for neuropathic pain, fibromyalgia, musculoskeletal pain. **TCAs** (amitriptyline, nortriptyline): effective analgesics at sub-antidepressant doses; limited by side effects. SSRIs have less robust evidence for analgesia.

### Anticonvulsants

**Gabapentin** and **pregabalin**: first-line for neuropathic pain; monitor for misuse potential. Carbamazepine: specific efficacy in trigeminal neuralgia.

### Other Agents

**Topical agents**: lidocaine patches, capsaicin. **Muscle relaxants**: cyclobenzaprine, tizanidine (short-term use) **Ketamine**: emerging evidence for treatment-resistant chronic pain and depression; IV infusions or intranasal. **Cannabis**: growing patient use; mixed evidence, legal complexity, psychiatric risks.

![Table comparing non-opioid pharmacological options for chronic pain by mechanism, indications, and key side effects](/images/psychiatry/non-opioid-pain-pharmacotherapy.png)

## Psychotherapeutic Approaches

**Cognitive-behavioral therapy for chronic pain (CBT-CP)**: the best-studied psychological treatment; addresses catastrophizing, avoidance, and maladaptive cognitions. **Acceptance and commitment therapy (ACT)**: promotes psychological flexibility and engagement with values despite pain. **Mindfulness-based stress reduction (MBSR)**: reduces pain catastrophizing and improves function. **Biofeedback and relaxation training**: effective adjuncts for tension-type headache, fibromyalgia. **Interdisciplinary pain rehabilitation programs**: combine physical therapy, psychology, occupational therapy, and medical management.

## Opioid Use Disorder: Identification and Treatment

Screen for OUD using **DSM-5 criteria**: loss of control, craving, tolerance, withdrawal, continued use despite harm. **Medication-assisted treatment (MAT)** is the standard of care: **Buprenorphine/naloxone**: partial mu-opioid agonist; can be prescribed in outpatient settings. **Methadone**: full agonist; dispensed through OTPs (opioid treatment programs) **Extended-release naltrexone**: mu-opioid antagonist; requires full detoxification first. Combine MAT with psychosocial interventions (contingency management, CBT, mutual support groups) Address psychiatric comorbidities concurrently.

![Infographic showing the three FDA-approved medications for opioid use disorder with their mechanisms and key clinical features](/images/psychiatry/mat-opioid-use-disorder.png)

## Key Clinical Pearls

Chronic pain and depression are neurobiologically intertwined; treating one without addressing the other leads to poor outcomes for both. SNRIs and TCAs offer dual benefit for patients with comorbid pain and depression; SSRIs are less effective for pain. Every patient on chronic opioid therapy should have a naloxone prescription and an ongoing risk-benefit assessment. Interdisciplinary pain rehabilitation programs produce the best long-term outcomes for chronic pain; passive, procedure-based approaches often perpetuate disability.

## References

1. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain — United States, 2022. *MMWR Recomm Rep*. 2022;71(3):1-95.
2. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. *Arch Intern Med*. 2003;163(20):2433-2445.
3. Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and treatment of opioid misuse and addiction. *JAMA Psychiatry*. 2019;76(2):208-216.
4. Williams ACC, Fisher E, Hearn L, Eccleston C. Psychological therapies for the management of chronic pain (excluding headache) in adults. *Cochrane Database Syst Rev*. 2020;8:CD007407.